国家计委一纸药品限价令发下,合资药企——强生、史克、施贵宝不仅停止向零售终端供货,而且同时向国家计委提起价格复议;药品销售商则不动声色地把降价令搁在了一旁;医院则大玩“变通之术”,在降价药品名称上大做文章;而此项决策最大的受益人——消费者却因为不能享有充分的知情权,支持的声音也不响亮。这个限价令的地位实在有些尴尬。 State Pharmaceutical Commission issued a paper limit orders, joint ventures - Johnson & Johnson, Shi Ke, Bristol-Myers Squibb not only to stop the supply of retail terminals, but at the same time to the State Development Planning Commission for price reconsideration; drug vendors are quietly put The price reduction put aside; the hospital is playing a “workaround” in the name of the price tag on a big fuss; and the biggest beneficiary of this decision - consumers because they can not have full access to information, the voice of support Not loud. The status of this limit order is somewhat embarrassing.